ARTICLE | Company News
Rexahn, National Cancer Institute deal
July 27, 2015 7:00 AM UTC
Rexahn said the NCI’s Nanotechnology Characterization Laboratory (NCL) accepted RX-21101 for a preclinical characterization program, which Rexahn said will facilitate movement of the cancer compound ...